SEC Filings
FIGS Sales Climb 25.7% As Expenses Grow More Slowly — Company Raises Annual Forecasts
International sales grew 51.4%, while quarterly net profit reached $19.3 million, compared with $8.7 million a year earlier.
SEC Filings
International sales grew 51.4%, while quarterly net profit reached $19.3 million, compared with $8.7 million a year earlier.
SEC Filings
Worldwide sales rose 14% on both reported and currency-neutral bases, while Tandem kept its annual forecast unchanged.
SEC Filings
The cell-therapy developer expects autoimmune-disease results Monday and a lymphoma trial update in mid-2027.
SEC Filings
A $100 million Genentech payment and an October share sale are expected to help fund operations into the second half of 2029.
SEC Filings
Exon-skipping drugs lifted the sales forecast floor, while a smaller research bill helped narrow the quarterly loss.
SEC Filings
The medical-products maker kept its 2026 forecast intact but expects results toward the higher end of its ranges.
SEC Filings
Veppanu brought in $6.6 million in initial sales, while Rigel narrowed its annual revenue outlook, which excludes the breast-cancer drug.
SEC Filings
Gilbert will take over January 1 while TransUnion continues its search for a permanent finance chief.
SEC Filings
The optical-networking supplier returned to profit, but power access and construction issues are delaying its U.S. expansion.
SEC Filings
The largest slice matures in 2030, while €750 million carries interest tied to three-month EURIBOR.
SEC Filings
The optional program lets Fate set sale limits and pays Leerink up to 3% of gross proceeds.
SEC Filings
Takeda is running three late-stage elritercept trials, with payments tied to dosing the first patients.